Polymer-coated crosslinked alginate gel fiber

Patent metadata

Field	Value
Publication number	US-12312574-B2
Application number	US-202318392583-A
Country	US
Kind code	B2
Filing date	Dec 21, 2023
Priority date	Jun 23, 2021
Publication date	May 27, 2025
Grant date	May 27, 2025

Abstract

There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic β cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

First claim

The invention claimed is:

1. A polymer-coated crosslinked alginate gel fiber consisting of:
a core layer; and
a cationic polymer layer, wherein the cationic polymer layer is selected from the group consisting of poly-L-ornithine (PLO), polymethylene-CO-guanidine (PMCG), polyallylamine (PAA), and polyethyleneimine,
wherein the core layer comprises an antibody-producing cell or a bioactive substance-producing cell embedded in crosslinked alginate gel that is obtained by performing a crosslinking reaction using chemically modified alginic acid derivatives represented by Formula (I) and Formula (II), and
the cationic polymer layer coats the surface of the core layer,
wherein the polymer-coated crosslinked alginate gel fiber has a length within a range of 0.01 to 100 m and is suitable for use in the production of at least one member selected from the group consisting of an antibody and a bioactive substance, and
wherein the chemically modified alginic acid derivative represented by Formula (I) is a chemically modified alginic acid derivative represented by Formula (I) below:

in Formula (I), (ALG) represents alginic acid; —NHCO— represents an amide bond through an arbitrary carboxyl group of the alginic acid; wherein Akn represents a cyclic alkyne group; -L 1 - is a divalent linker that bonds to the cyclic alkyne group (Akn), Akn-L 1 - is a group selected from the group consisting of the partial structural formulae shown in the following table, wherein in each formula, the right side of the broken line is not included:

No.
Akn—L 1 —

ALK- 1a

x1a = 1-6

ALK- 1b

x1b = 1-6 y1b = 1-6

ALK- 2

x2 = 1-6 y2 = 0-6 z2 = 1-6

ALK- 3a

x3a = 1-6 y3a = 0-6 z3a = 2-6

ALK- 3b

x3b = 1-6 y3b = 0-6 z3b = 1-6

ALK- 4

x4 = 1-6 y4 = 2-6

ALK- 5a

x5a = 1-6 y5a = 2-6 z5a = 2-6

ALK- 5b

x5b = 1-6 y5b = 1-6 z5b = 2-6

TABLE 72-2

No.
Akn—L 1 —

ALK- 6

x6 = 1-6 y6 = 1-6 z6 = 2-6

ALK- 7a

x7a = 1-6 y7a = 2-6 z7a = 2-6 v7a = 1-6

ALK- 7b

x7b = 1-6 y7b = 1-6 z7b = 2-6 v7b = 1-6

and
the chemically modified alginic acid derivative represented by Formula (II) is a chemically modified alginic acid derivative represented by Formula (II) below:

in Formula (II), (ALG) represents alginic acid; —NHCO— represents an amide bond through an arbitrary carboxyl group of the alginic acid; -L 2 - represents a linker selected from the group consisting of partial structural formulae, wherein in each formula, the outsides of the broken lines at both ends are not included, shown in the following table:

No.
—L 2 —

LN- 1

a1 = 2-6 b1 = 2-6

Assignees

• Mochida Pharm Co Ltd

Inventors

• Furusako Shoji
• Satoh Tsutomu
• Narumi Tomohiro
• Sato Shingo

Classifications

• C12N11/04 Primary

  entrapped within the carrier, e.g. gel or hollow fibres · CPC title

• C12N5/0682

  Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609) · CPC title

• C12N5/0676

  Pancreatic cells · CPC title

• C12M23/20

  Material Coatings (immunocoatings C12M25/00) · CPC title

• C08L5/04

  Alginic acid; Derivatives thereof · CPC title